Infant botulism

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

2 events
Mar 2026GAMIFANT: New indication approved
FDAcompleted
Oct 2003

BabyBIG: FDA approved

Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum.

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

BabyBIG

California Department of Public Health

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

BabyBIG

(Botulism immune globulin)Orphan drug

California Department of Public Health

Human Immunoglobulin G [EPC]

12.1 Mechanism of Action BabyBIG contains antibodies specific for botulinum neurotoxin types A and B that bind to and neutralize circulating toxin typ...

Approved Oct 2003FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Infant botulism.
Search all trials →
Search clinical trials for Infant botulism

Recent News & Research

1 article
BREAKINGFDA

FDA Approves GAMIFANT

GAMIFANT (EMAPALUMAB-LZSG) received FDA approval.

Read ↗

Browse all Infant botulism news →

Specialist Network

Top 6 by expertise

View all Infant botulism specialists →

Quick Actions